指南与共识骨软组织肉瘤与黑色素瘤支持与姑息治疗

欧洲跨学科指南:侵袭性皮肤鳞状细胞癌治疗(第二部分)

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
指南 / 共识 · Eur J Cancer · 2020-02-26

该指南由欧洲皮肤病论坛、欧洲皮肤肿瘤协会和欧洲癌症研究与治疗组织多学科专家组制定,基于循证文献回顾、指南和专家共识,针对常见原发性(低危、高危)、局部晚期、区域转移(可手术或不可手术)及远处转移性皮肤鳞状细胞癌提出治疗推荐。一线治疗为手术切除配合术后切缘评估或显微镜控制手术,晚期患者一线系统治疗为抗PD-1抗体。

要点

  • 常见原发性cSCC一线治疗为手术切除并评估切缘或显微镜控制手术。
  • 可手术病例切缘阳性应再切除,区域淋巴结确诊转移者推荐淋巴结清扫。
  • 不可手术或非手术候选者考虑放疗根治,晚期一线系统治疗为抗PD-1抗体。

核心结论

  • 常见原发性cSCC首选手术切除并确保阴性切缘以降低局部复发和转移风险。
  • 晚期cSCC一线系统治疗为抗PD-1抗体,二线包括EGFR抑制剂联合化疗或放疗。

研究设计与样本

  • 由欧洲皮肤病论坛、欧洲皮肤肿瘤协会和欧洲癌症研究与治疗组织多学科专家组制定,基于循证文献回顾、指南和专家共识。

主要发现

  • 治疗推荐按常见原发性(低危、高危)、局部晚期、区域转移(可手术或不可手术)和远处转移性cSCC分层呈现。
  • 手术切除需包含肿瘤周围临床正常外观组织作为安全切缘,病理报告阴性切缘是必要的。
  • 可手术病例切缘阳性应再切除,细胞学或组织学确诊区域淋巴结受累者推荐淋巴结清扫。
  • 不可手术cSCC或非手术候选者应考虑放疗作为根治性治疗。
  • 转移性或局部晚期且不适合根治性手术或放疗者一线系统治疗为抗PD-1抗体,cemiplimab是FDA/EMA首个获批用于晚期cSCC的系统药物。

关键数值与推荐

  • 常见原发性cSCC一线治疗为手术切除配合术后切缘评估或显微镜控制手术。
  • 可手术病例切缘阳性应再切除。
  • 细胞学或组织学确诊区域淋巴结受累者推荐淋巴结清扫。
  • 不可手术cSCC或非手术候选者考虑放疗根治。
  • 转移性或局部晚期不适合根治性手术或放疗者一线系统治疗为抗PD-1抗体。

临床怎么用

  • 所有需要超过手术治疗的晚期患者必须经多学科委员会决策。
  • 患者应参与知情管理决策,并获得最佳支持治疗以优化症状管理和改善生活质量。
  • 随访频率和检查项目取决于潜在风险特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In order to update recommendations on treatment, supportive care, education and follow-up of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary panel of experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer was formed. Recommendations were based on evidence-based literature review, guidelines and expert consensus. Treatment recommendations are presented for common primary cSCC (low risk, high risk), locally advanced cSCC, regional metastatic cSCC (operable or inoperable) and distant metastatic cSCC. For common primary cSCC (the most frequent cSCC type), first-line treatment is surgical excision with postoperative margin assessment or microscopically controlled sugery. Safety margins containing clinical normal-appearing tissue around the tumour during surgical excision and negative margins as reported in the pathology report are necessary to minimise the risk of local recurrence and metastasis. In case of positive margins, a re-excision shall be done, for operable cases. Lymph node dissection is recommended for cSCC with cytologically or histologically confirmed regional nodal involvement. Radiotherapy should be considered as curative treatment for inoperable cSCC, or for non-surgical candidates. Anti-PD-1 antibodies are the first-line systemic treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drug Administration/European Medicines Agency. Second-line systemic treatments for advanced cSCC include epidermal growth factor receptor inhibitors (cetuximab) combined with chemotherapy or radiation therapy. Multidisciplinary board decisions are mandatory for all patients with advanced disease who require more than surgery. Patients should be engaged with informed decisions on management and be provided with best supportive care to optimise symptom management and improve quality of life. Frequency of follow-up visits and investigations for subsequent new cSCC depend on underlying risk characteristics.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020. PMID: 32113942. doi:10.1016/j.ejca.2020.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。